Kline Kyle 4

What Happened

Kyle Kline, Senior Vice President and Chief Financial Officer of Globus Medical (GMED), was granted 30,000 stock option awards on January 21, 2026. The grant is reported as a derivative award (price reported $0.00 — no cash paid at grant). This is an equity compensation award rather than a market purchase or sale.

Key Details

• Transaction date: 2026-01-21 (reported on Form 4 filed 2026-01-23).
• Amount: 30,000 option awards; reported acquisition price $0.00 (award/grant).
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Footnote: Options vest over four years — 1/4 vest on Jan 1, 2027, then 1/48 of the grant vests monthly thereafter.
• Timeliness: Filing appears timely (transaction 1/21/2026; Form 4 filed 1/23/2026).

Context

• This is a grant of options (a derivative award); no shares were sold or purchased in the open market and no immediate proceeds or cashless exercise occurred.
• Equity grants to executives are common compensation and do not by themselves indicate the insider is buying or selling stock.